Clinical Trial Update: TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of transarterial chemoembolization (TACE), sorafenib, and a PD-1 monoclonal antibody for hepatocellular carcinoma has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• PD-1 monoclonal antibody
• Sorafenib (Sorafenib)

Snippet

Sponsor: Sichuan Cancer Hospital and Research Institute | Conditions: Hepatocellular Carcinoma, Liver Neoplasms | Phase 2 | Status: COMPLETED